ArticleScientific reports2017
Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05554146 (The Impact of Medical Cannabis on Pain and Inflammation in People Living With HIV), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Medical Cannabis on Pain and Inflammation in People Living With HIV
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies.The American journal of psychiatry · 2025Pooled it
- Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.Journal of psychopharmacology (Oxford, England) · 2018Pooled it
- Investigating the Relationship Between Cannabis Expectancies and Anxiety, Depression, and Pain Responses After Acute Flower and Edible Cannabis Use.Cannabis and cannabinoid research · 2025Trial
- Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-ExperimentalCannabis and cannabinoid research · 2024Trial
- Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.Drug and alcohol dependence · 2024Trial
- Effects of cannabidiol in cannabis flower: Implications for harm reduction.Addiction biology · 2022Trial
- Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain.Psychopharmacology · 2026Article
- Operationalizing ASSIST-based indicators to estimate the prevalence and correlates of problematic cannabis involvement among U.S. college students.Journal of cannabis research · 2026Article
- The Structure of the Chemotype Determining Locus inPlant direct · 2026Article
- Effects of legal-market cannabis and alcohol on verbal learning and memory.Psychopharmacology · 2026Article
- A Systematic Review: Investigating Biomarkers of Anhedonia and Amotivation in Depression and Cannabis Use.JAACAP open · 2025Review
- Cannabis administration is associated with reduced alcohol consumption: Evidence from a novel laboratory co-administration paradigm.Drug and alcohol dependence · 2025Article
- Potential role of cannabis in ameliorating observed racialized disparities in cancer pain management.Journal of the National Cancer Institute · 2024Article
- Meaningfully Characterizing Cannabis Use for Research and Clinical Settings: A Comprehensive Review of Existing Measures and Proposed Future Directions.Psychiatry and clinical psychopharmacology · 2024Review
- The impact of recreational cannabis legalization on youth: the Colorado experience.European child & adolescent psychiatry · 2024Review
- Effects of acute ΔBrain research · 2024Article
- Edible cannabis for chronic low back pain: associations with pain, mood, and intoxication.Frontiers in pharmacology · 2024Article
- Effects of historical inequity and institutional power on cannabis research: Moving toward equity and inclusion.PNAS nexus · 2023Article
- THC in breath aerosols collected with an impaction filter device before and after legal-market product inhalation-a pilot study.Journal of breath research · 2023Article
- Combined ambient ionization mass spectrometric and chemometric approach for the differentiation of hemp and marijuana varieties of Cannabis sativa.Journal of cannabis research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
As the most widely used illicit drug worldwide, and as a source of numerous under-studied pharmacologically-active compounds, a precise understanding of variability in psychological and physiological effects of Cannabis varieties is essential. The National Institute on Drug Abuse (NIDA) is designated as the sole legal producer of Cannabis for use in US research studies. We sought to compare the chemical profiles of Cannabis varieties that are available to consumers in states that have state-legalized use versus what is available to researchers interested in studying the plant and its effects. Our results demonstrate that the federally-produced Cannabis has significantly less variety and lower concentrations of cannabinoids than are observed in state-legal U.S. dispensaries. Most dramatically, NIDA's varieties contain only 27% of the THC levels and as much as 11-23 times the Cannabinol (CBN) content compared to what is available in the state-legal markets. Research restricted to using the current range of federally-produced Cannabis thus may yield limited insights into the chemical, biological and pharmacological properties, and medical potential of material that is available in the state markets. Investigation is urgently needed on the full diversity of Cannabis chemotypes known to be available to the public.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.